

28 September 2022

ASX Announcement

## Notice of Annual General Meeting and Closing Date for Director Nominations

---

**Firebrick Pharma Limited** (ASX: FRE) (**Company** or **Firebrick**) advises that the Company's Annual General Meeting (AGM) is scheduled to be convened at 3.00pm (AEDT) on Wednesday, 23 November 2022.

The AGM will be held at the offices of Chartered Accountants Australia and New Zealand, Level 18, 600 Bourke Street, Melbourne, Victoria.

In accordance with the Company's Constitution, the closing date for receipt of director nominations to the Company from persons wishing to be considered for election as a director, is Wednesday, 5 October 2022. Any nominations must be received in writing at the Company's registered office by 5.00pm (AEDT).

The AGM materials will be produced and provided to shareholders in due course.

This announcement has been authorised for released by the Board of Firebrick Pharma Limited.

- ENDS -

## About Firebrick Pharma

Firebrick is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company subsequently developed Nasodine® Nasal Spray (“Nasodine”) and owns numerous granted and pending patents, including a core patent family that covers the use of Nasodine for the treatment and prevention of the common cold. The Company also owns a patent family that covers the use of Nasodine for the prevention of pandemic viral diseases, including COVID-19. Firebrick is currently undertaking two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

### Media enquiries:

Heidi Cuthbert  
+61 411 272 366  
[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

### Investor enquiries:

[Investors@firebrickpharma.com](mailto:Investors@firebrickpharma.com)